E. M. Blessing, M. M. Steenkamp, J. Manzanares, and C. R. Marmar, Cannabidiol as a Potential Treatment for Anxiety Disorders, Neurotherapeutics. oct, vol.12, issue.4, pp.825-861, 2015.

J. Lee, L. J. Bertoglio, F. S. Guimarães, and C. W. Stevenson, Cannabidiol regulation of emotion and emotional memory processing: relevance for treating anxiety-related and substance abuse disorders: CBD regulation of fear and drug reward processing, British Journal of Pharmacology, vol.174, pp.3242-56, 2017.

Y. Gaoni and R. Mechoulam, Isolation, Structure, and Partial Synthesis of an Active Constituent of Hashish, Journal of the American Chemical Society. avr, vol.86, issue.8, pp.1646-1653, 1964.

A. C. Campos, F. A. Moreira, F. V. Gomes, D. Bel, E. A. Guimaraes et al., Multiple mechanisms involved in the large-spectrum therapeutic potential of cannabidiol in psychiatric disorders, Philosophical Transactions of the Royal Society B: Biological Sciences. 5 déc, vol.367, pp.3364-78, 1607.

J. Corroon and R. Kight, Regulatory Status of Cannabidiol in the United States: A Perspective. Cannabis and Cannabinoid Research, sept, vol.3, issue.1, pp.190-194, 2018.

Y. Jagailloux, J. Lelong, P. Mura, and B. Brunet, Aspects légaux et analyse de produits à base de cannabidiol, Toxicologie Analytique et Clinique. mai, vol.31, issue.2, pp.48-57, 2019.

. Bonn-miller, . Mo, M. Loflin, B. F. Thomas, J. P. Marcu et al., Labeling Accuracy of Cannabidiol Extracts Sold Online, JAMA, vol.318, issue.17, p.1708, 2017.

B. Angerville and A. Dervaux, Le cannabidiol : état des lieux, Disponible sur, 2018.

M. Premoli, F. Aria, S. A. Bonini, G. Maccarinelli, A. Gianoncelli et al., Cannabidiol: Recent advances and new insights for neuropsychiatric disorders treatment, Life Sci. 1 mai, vol.224, pp.120-127, 2019.

C. Rong, Y. Lee, N. E. Carmona, D. S. Cha, R. Ragguett et al., Cannabidiol in medical marijuana: Research vistas and potential opportunities, Pharmacological Research. juill, vol.121, pp.213-221, 2017.

B. Angerville and A. Dervaux, Cannabidiol : où en est-on ? Le Courrier des Addictions, Disponible sur, 2017.

C. M. White, A Review of Human Studies Assessing Cannabidiol's (CBD) Therapeutic Actions and Potential. The Journal of Clinical Pharmacology, vol.7

D. Sur,

M. M. Bergamaschi, R. Queiroz, M. Chagas, D. De-oliveira, D. Martinis et al., Cannabidiol Reduces the Anxiety Induced by Simulated Public Speaking in Treatment-Naïve Social Phobia Patients, Neuropsychopharmacology. mai, vol.36, issue.6, pp.1219-1245, 2011.

F. V. Gomes, R. Llorente, D. Bel, E. A. Viveros, M. López-gallardo et al., Decreased glial reactivity could be involved in the antipsychotic-like effect of cannabidiol, Schizophrenia Research. mai, vol.164, issue.1-3, pp.155-63, 2015.

F. M. Leweke, D. Piomelli, F. Pahlisch, D. Muhl, C. W. Gerth et al., Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia, Transl Psychiatry. mars, vol.2, issue.3, pp.94-94, 2012.

P. Mcguire, P. Robson, W. J. Cubala, D. Vasile, P. D. Morrison et al., Cannabidiol (CBD) as an Adjunctive Therapy in Schizophrenia: A Multicenter Randomized Controlled Trial, AJP. mars, vol.175, issue.3, pp.225-256, 2018.

M. Machado-bergamaschi, H. C. Queiroz, R. , W. Zuardi, A. et al., Safety and Side Effects of Cannabidiol, a Cannabis sativa Constituent, Current Drug Safety. 1 sept, vol.6, issue.4, pp.237-286, 2011.

K. Iffland and F. Grotenhermen, An Update on Safety and Side Effects of Cannabidiol: A Review of Clinical Data and Relevant Animal Studies. Cannabis and Cannabinoid Research, janv, vol.2, issue.1, pp.139-54, 2017.

D. Samanta, Cannabidiol: A Review of Clinical Efficacy and Safety in Epilepsy, Pediatric Neurology. mars, p.0887899418311688, 2019.

, WHO | Controlled substances

D. Sur,

, Usage médical du cannabis et des cannabinoïdes: questions et réponses à l'intention des décideurs politiques. Luxembourg: Observatoire européen des drogues et des toxicomanies, 2019.

S. Lecjzak, Cannabis et cannabidiol : éléments de compréhension

J. Gonçalves, T. Rosado, S. Soares, A. Y. Simão, D. Caramelo et al., Cannabis and Its Secondary Metabolites: Their Use as Therapeutic Drugs, Toxicological Aspects, and Analytical Determination. Medicines (Basel). 23 févr, vol.6, issue.1, 2019.

, Luxembourg: Observatoire européen des drogues et des toxicomanies, Rapport européen sur les drogues 2019 : Tendances et évolutions, 2019.

. Commissioner-o-of-the, FDA Regulation of Cannabis and Cannabis-Derived Products: Questions and Answers. FDA [Internet]. 4 mars, 2019.

, Disponible sur: /newsevents/public-health-focus/fda-regulation-cannabis-and-cannabis-derived-products-questionsand-answers

, Avis issu de la première concertation organisée par le RESPADD sur la vaporisation du CBD -RESPADD

, Cannabidiol (CBD) le point sur la législation

D. Sur,

, Arrêté du 22 août 1990 portant application de l'article R. 5132-86 du code de la santé publique pour le cannabis

, Vapoteuse au chanvre: la cour d'appel saisit la CJUE

D. Sur,

N. Authier, M. Bonnet, D. Haro, L. Delile, J. Grégoire et al., Commission des stupéfiants et psychotropes. Agence Nationale de Sécurité du Médicament et des produits de santé, p.11, 2018.

, Commission de la transparence : SATIVEX, solution pour pulvérisation buccale

H. Autorité-de-santé, Cannabis à visée thérapeutique en France : le comité d'experts poursuit son programme de travail -Point d'Information -ANSM : Agence nationale de sécurité du médicament et des produits de santé, 2014.

A. Bettiol, N. Lombardi, G. Crescioli, V. Maggini, E. Gallo et al., Galenic Preparations of Therapeutic Cannabis sativa Differ in Cannabinoids Concentration: A Quantitative Analysis of Variability and Possible Clinical Implications, Front Pharmacol, vol.9, p.1543, 2018.

N. Authier, G. Brousse, L. Copel, G. Edan, B. Jarraya et al., Comité scientifique spécialisé temporaire « évaluation de la pertinence et de la faisabilité de la mise à disposition du cannabis thérapeutique en France ». Agence Nationale de Sécurité du Médicament et des produits de santé, 2018.

M. Crocq and J. D. Guelfi, American Psychiatric Association. DSM-5 ®: manuel diagnostique et statistique des troubles mentaux, 2016.

D. S. Hasin, E. Greenstein, C. Aivadyan, M. Stohl, E. Aharonovich et al., The Alcohol Use Disorder and Associated Disabilities Interview Schedule-5 (AUDADIS-5): procedural validity of substance use disorders modules through clinical re-appraisal in a general population sample, Drug Alcohol Depend. 1 mars, vol.148, pp.40-46, 2015.

R. A. Grucza, A. Agrawal, M. J. Krauss, P. A. Cavazos-rehg, and L. J. Bierut, Recent Trends in the Prevalence of Marijuana Use and Associated Disorders in the United States, JAMA Psychiatry. mars, vol.73, issue.3, pp.300-301, 2016.

D. S. Hasin, B. T. Kerridge, T. D. Saha, B. Huang, R. Pickering et al., Prevalence and Correlates of DSM-5 Cannabis Use Disorder, 2012-2013: Findings from the National Epidemiologic Survey on Alcohol and Related Conditions-III, Am J Psychiatry, vol.01, issue.6, pp.588-99, 2016.

S. Spilka, J. Richard, L. Nézet, O. Janssen, E. Brissot et al., Les niveaux d'usage des drogues illicites en France en 2017. Observatoire français des drogues et des toxicomanies, 2018.

K. M. Carroll, C. Nich, D. M. Lapaglia, E. N. Peters, C. J. Easton et al., Combining cognitive behavioral therapy and contingency management to enhance their effects in treating cannabis dependence: less can be more, more or less, Addiction. sept, vol.107, issue.9, pp.1650-1659, 2012.

A. J. Budney, B. A. Moore, H. L. Rocha, and S. T. Higgins, Clinical trial of abstinence-based vouchers and cognitive-behavioral therapy for cannabis dependence, J Consult Clin Psychol. avr, vol.74, issue.2, pp.307-323, 2006.

A. J. Budney, R. G. Vandrey, and C. Stanger,

J. Braz, . Psychiatry, and . Mai, , vol.32, pp.46-55, 2010.

B. J. Sherman and A. L. Mcrae-clark, Treatment of Cannabis Use Disorder: Current Science and Future Outlook, Pharmacotherapy, vol.36, issue.5, pp.511-546, 2016.

Y. Chye, E. Christensen, N. Solowij, and M. Yücel, The Endocannabinoid System and Cannabidiol's Promise for the Treatment of Substance Use Disorder, Front Psychiatry, vol.10, p.63, 2019.

S. Nielsen, L. Gowing, P. Sabioni, L. Foll, and B. , Pharmacotherapies for cannabis dependence, Cochrane Database Syst Rev, vol.28, p.8940, 2019.

A. T. Mclellan, D. C. Lewis, C. P. O'brien, and H. D. Kleber, Drug dependence, a chronic medical illness: implications for treatment, insurance, and outcomes evaluation, JAMA, vol.284, issue.13, pp.1689-95, 2000.

M. Haney, C. L. Hart, S. K. Vosburg, S. D. Comer, S. C. Reed et al., Effects of THC and lofexidine in a human laboratory model of marijuana withdrawal and relapse, Psychopharmacology (Berl). mars, vol.197, issue.1, pp.157-68, 2008.

F. R. Levin, J. J. Mariani, D. J. Brooks, M. Pavlicova, W. Cheng et al., Dronabinol for the treatment of cannabis dependence: a randomized, double-blind, placebo-controlled trial, Drug Alcohol Depend. 1 juill, vol.116, issue.1-3, pp.142-50, 2011.

R. Vandrey, M. L. Stitzer, M. Z. Mintzer, M. A. Huestis, J. A. Murray et al., The dose effects of short-term dronabinol (oral THC) maintenance in daily cannabis users, Drug Alcohol Depend. 1 févr, vol.128, issue.1-2, pp.64-70, 2013.

, MARINOL 2,5 mg, capsule molle -ANSM : Agence nationale de sécurité du médicament et des produits de santé

M. Haney, Z. D. Cooper, G. Bedi, S. K. Vosburg, S. D. Comer et al., Nabilone decreases marijuana withdrawal and a laboratory measure of marijuana relapse, Neuropsychopharmacology. juill, vol.38, issue.8, pp.1557-65, 2013.

L. V. Panlilio, Z. Justinova, J. M. Trigo, L. Foll, and B. , Screening Medications for the Treatment of Cannabis Use Disorder, Int Rev Neurobiol, vol.126, pp.87-120, 2016.

E. S. Herrmann, Z. D. Cooper, G. Bedi, R. D. Reed, S. C. Comer et al., Effects of zolpidem alone and in combination with nabilone on cannabis withdrawal and a laboratory model of relapse in cannabis users, Psychopharmacology (Berl), vol.233, issue.13, pp.2469-78, 2016.

N. Authier, M. Becchio, M. Bonnet, C. Magnin, M. Mallaret et al., Commission des stupéfiants et psychotropes

, Agence Nationale de Sécurité du Médicament et des produits de santé, 2013.

D. J. Allsop, J. Copeland, N. Lintzeris, A. J. Dunlop, M. Montebello et al., Nabiximols as an agonist replacement therapy during cannabis withdrawal: a randomized clinical trial, JAMA Psychiatry. mars, vol.71, issue.3, pp.281-91, 2014.

J. M. Trigo, A. Soliman, L. C. Quilty, B. Fischer, J. Rehm et al., Nabiximols combined with motivational enhancement/cognitive behavioral therapy for the treatment of cannabis dependence: A pilot randomized clinical trial, PLoS ONE, vol.13, issue.1, p.190768, 2018.

A. Batalla, H. Janssen, S. S. Gangadin, and M. G. Bossong, The Potential of Cannabidiol as a Treatment for Psychosis and Addiction: Who Benefits Most? A Systematic Review, JCM. 19 juill, vol.8, issue.7, p.1058, 2019.

P. Maccioni, G. Colombo, and M. Carai, Blockade of the cannabinoid CB1 receptor and alcohol dependence: preclinical evidence and preliminary clinical data, CNS Neurol Disord Drug Targets. mars, vol.9, issue.1, pp.55-64, 2010.

C. Cohen, G. Perrault, G. Griebel, and P. Soubrié, Nicotine-associated cues maintain nicotine-seeking behavior in rats several weeks after nicotine withdrawal: reversal by the cannabinoid (CB1) receptor antagonist, rimonabant (SR141716), Neuropsychopharmacology. janv, vol.30, issue.1, pp.145-55, 2005.

M. A. Huestis, S. J. Boyd, S. J. Heishman, K. L. Preston, D. Bonnet et al., Single and multiple doses of rimonabant antagonize acute effects of smoked cannabis in male cannabis users. Psychopharmacology (Berl), vol.194, pp.505-520, 2007.

R. Christensen, P. K. Kristensen, E. M. Bartels, H. Bliddal, and A. Astrup, Efficacy and safety of the weightloss drug rimonabant: a meta-analysis of randomised trials, Lancet, vol.17, issue.9600, pp.1706-1719, 2007.

I. G. Karniol and E. A. Carlini, Pharmacological interaction between cannabidiol and ?9-tetrahydrocannabinol, Psychopharmacologia, vol.33, issue.1, pp.53-70, 1973.

A. W. Zuardi, N. A. Teixeira, and I. C. Karniol, Pharmacological interaction of the effects of delta 9-transtetrahydrocannabinol and cannabidiol on serum corticosterone levels in rats, Arch Int Pharmacodyn Ther. mai, vol.269, issue.1, pp.12-21, 1984.

J. T. Pickens, Sedative activity of cannabis in relation to its delta'-trans-tetrahydrocannabinol and cannabidiol content, Br J Pharmacol. avr, vol.72, issue.4, pp.649-56, 1981.

R. Mechoulam, L. A. Parker, and R. Gallily, Cannabidiol: an overview of some pharmacological aspects, J Clin Pharmacol, vol.42, issue.S1, pp.11-19, 2002.

E. S. Onaivi, M. R. Green, and B. R. Martin, Pharmacological characterization of cannabinoids in the elevated plus maze, J Pharmacol Exp Ther. juin, vol.253, issue.3, pp.1002-1011, 1990.

A. J. Hiltunen and T. U. Järbe, Cannabidiol attenuates delta 9-tetrahydrocannabinol-like discriminative stimulus effects of cannabinol, Eur J Pharmacol. 17 juin, vol.125, issue.2, pp.301-305, 1986.

R. E. Vann, T. F. Gamage, J. A. Warner, E. M. Marshall, N. L. Taylor et al., Divergent effects of cannabidiol on the discriminative stimulus and place conditioning effects of ?9-tetrahydrocannabinol. Drug and Alcohol Dependence, avr, vol.94, issue.1-3, pp.191-199, 2008.

C. Klein, E. Karanges, A. Spiro, A. Wong, J. Spencer et al., Cannabidiol potentiates ? 9 -tetrahydrocannabinol (THC) behavioural effects and alters THC pharmacokinetics during acute and chronic treatment in adolescent rats, Psychopharmacology (Berl), vol.218, issue.2, pp.443-57, 2011.

I. G. Karniol, I. Shirakawa, N. Kasinski, A. Pfeferman, and E. A. Carlini, Cannabidiol interferes with the effects of ?9-tetrahydrocannabinol in man, European Journal of Pharmacology. sept, vol.28, issue.1, pp.172-179, 1974.

A. W. Zuardi, I. Shirakawa, E. Finkelfarb, and I. G. Karniol, Action of cannabidiol on the anxiety and other effects produced by delta 9-THC in normal subjects, Psychopharmacology (Berl), vol.76, issue.3, pp.245-50, 1982.

A. Englund, P. D. Morrison, J. Nottage, D. Hague, F. Kane et al., Cannabidiol inhibits THC-elicited paranoid symptoms and hippocampal-dependent memory impairment, J Psychopharmacol (Oxford). janv, vol.27, issue.1, pp.19-27, 2013.

N. Solowij, S. J. Broyd, C. Beale, J. Prick, L. Greenwood et al., Therapeutic Effects of Prolonged Cannabidiol Treatment on Psychological Symptoms and Cognitive Function in Regular Cannabis Users: A Pragmatic Open-Label Clinical Trial, Cannabis Cannabinoid Res, vol.3, issue.1, pp.21-34, 2018.

C. Morgan, G. Schafer, T. P. Freeman, and H. V. Curran, Impact of cannabidiol on the acute memory and psychotomimetic effects of smoked cannabis: naturalistic study: naturalistic study

, Br J Psychiatry, vol.197, issue.4, pp.285-90, 2010.

C. Morgan, T. P. Freeman, G. L. Schafer, and H. V. Curran, Cannabidiol attenuates the appetitive effects of Delta 9-tetrahydrocannabinol in humans smoking their chosen cannabis, Neuropsychopharmacology. août, vol.35, issue.9, pp.1879-85, 2010.

M. Haney, R. J. Malcolm, S. Babalonis, P. A. Nuzzo, Z. D. Cooper et al., Oral Cannabidiol does not Alter the Subjective, Reinforcing or Cardiovascular Effects of Smoked Cannabis, Neuropsychopharmacology, vol.41, issue.8, pp.1974-82, 2016.

S. Shannon and J. Opila-lehman, Cannabidiol Oil for Decreasing Addictive Use of Marijuana: A Case Report, Integr Med (Encinitas). déc, vol.14, issue.6, pp.31-36, 2015.

J. Crippa, .. S. Hallak, J. Machado-de-sousa, J. P. Queiroz, R. Bergamaschi et al., Cannabidiol for the treatment of cannabis withdrawal syndrome: a case report, J Clin Pharm Ther. avr, vol.38, issue.2, pp.162-166, 2013.

S. Bhattacharyya, P. D. Morrison, P. Fusar-poli, R. Martin-santos, S. Borgwardt et al., Opposite effects of delta-9-tetrahydrocannabinol and cannabidiol on human brain function and psychopathology, Neuropsychopharmacology. févr, vol.35, issue.3, pp.764-74, 2010.

M. Prud'homme, R. Cata, and D. Jutras-aswad, Cannabidiol as an Intervention for Addictive Behaviors: A Systematic Review of the Evidence, Subst Abuse, vol.9, pp.33-41, 2015.

, Cannabidiol Pharmacotherapy for Adults With Cannabis Use Disorder -Full Text View -ClinicalTrials

, Cannabidiol: a Novel Intervention for Cannabis Use Problems? -Full Text View -ClinicalTrials.gov, p.83

D. Sur,

, Cannabidiol (CBD) for the Management of Cannabis Withdrawal: A Phase II Proof of Concept Study -Full Text View -ClinicalTrials.gov

, Effects of Cannabidiol on Marijuana-seeking in Humans -Full Text View -ClinicalTrials.gov

D. Sur,

, Effects of Cannabidiol on Psychiatric Symptoms, Cognition, and Cannabis Consumption in Cannabis Users With Recent-Onset Psychosis -Full Text View -ClinicalTrials.gov

A. W. Zuardi, J. Hallak, and J. Crippa, Interaction between cannabidiol (CBD) and ?(9)-tetrahydrocannabinol (THC): influence of administration interval and dose ratio between the cannabinoids, Psychopharmacology (Berl). janv, vol.219, issue.1, pp.247-256, 2012.

A. W. Zuardi, Cannabidiol: from an inactive cannabinoid to a drug with wide spectrum of action, Braz J Psychiatry. sept, vol.30, issue.3, pp.271-80, 2008.

I. Svízenská, P. Dubový, and A. Sulcová, Cannabinoid receptors 1 and 2 (CB1 and CB2), their distribution, ligands and functional involvement in nervous system structures--a short review, Pharmacol Biochem Behav, vol.90, issue.4, pp.501-512, 2008.

M. Herkenham, A. B. Lynn, M. D. Little, M. R. Johnson, L. S. Melvin et al., Cannabinoid receptor localization in brain, Proc Natl Acad Sci, vol.87, issue.5, pp.1932-1938, 1990.

E. L. Gardner, Addictive potential of cannabinoids: the underlying neurobiology, Chem Phys Lipids. 31 déc, vol.121, issue.1-2, pp.267-90, 2002.

M. Reynaud, Traité d'addictologie, 2016.

E. D. French, K. Dillon, and X. Wu, Cannabinoids excite dopamine neurons in the ventral tegmentum and substantia nigra, Neuroreport. 10 févr, vol.8, issue.3, pp.649-52, 1997.

M. Solinas, S. R. Goldberg, and D. Piomelli, The endocannabinoid system in brain reward processes, Br J Pharmacol. mai, vol.154, issue.2, pp.369-83, 2008.
URL : https://hal.archives-ouvertes.fr/hal-00398409

H. Houchi, D. Babovic, O. Pierrefiche, C. Ledent, M. Daoust et al., CB1 receptor knockout mice display reduced ethanol-induced conditioned place preference and increased striatal dopamine D2 receptors, Neuropsychopharmacology. févr, vol.30, issue.2, pp.339-388, 2005.
URL : https://hal.archives-ouvertes.fr/inserm-00116578

G. Colombo, S. Serra, G. Brunetti, R. Gomez, S. Melis et al., Stimulation of voluntary ethanol intake by cannabinoid receptor agonists in ethanol-preferring sP rats, Psychopharmacology (Berl). janv, vol.159, issue.2, pp.181-188, 2002.

W. J. Lynch, K. L. Nicholson, M. E. Dance, R. W. Morgan, and P. L. Foley, Animal models of substance abuse and addiction: implications for science, animal welfare, and society, Comp Med. juin, vol.60, issue.3, pp.177-88, 2010.

S. E. Hyman and R. C. Malenka, Addiction and the brain: the neurobiology of compulsion and its persistence, Nat Rev Neurosci, vol.2, issue.10, pp.695-703, 2001.

G. L. Gerdeman, J. G. Partridge, C. R. Lupica, and D. M. Lovinger, It could be habit forming: drugs of abuse and striatal synaptic plasticity, Trends Neurosci. avr, vol.26, issue.4, pp.184-92, 2003.

D. Robbe, M. Kopf, A. Remaury, J. Bockaert, and O. J. Manzoni, Endogenous cannabinoids mediate longterm synaptic depression in the nucleus accumbens, Proc Natl Acad Sci, vol.99, issue.12, pp.8384-8392, 2002.

C. Stern, C. R. De-carvalho, L. J. Bertoglio, and R. N. Takahashi, Effects of Cannabinoid Drugs on Aversive or Rewarding Drug-Associated Memory Extinction and Reconsolidation, Neuroscience, vol.01, pp.62-80, 2018.

A. Thomas, G. L. Baillie, A. M. Phillips, R. K. Razdan, R. A. Ross et al., Cannabidiol displays unexpectedly high potency as an antagonist of CB1 and CB2 receptor agonists in vitro, Br J Pharmacol. mars, vol.150, issue.5, pp.613-636, 2007.

R. G. Pertwee, Pharmacology of cannabinoid CB1 and CB2 receptors, Pharmacol Ther, vol.74, issue.2, pp.129-80, 1997.

R. B. Laprairie, A. M. Bagher, M. Kelly, and E. M. Denovan-wright, Cannabidiol is a negative allosteric modulator of the cannabinoid CB1 receptor, Br J Pharmacol, vol.172, issue.20, pp.4790-805, 2015.

A. W. Zuardi and I. G. Karniol, Effects on variable-interval performance in rats of delta 9-tetrahydrocannabinol and cannabidiol, separately and in combination, Braz J Med Biol Res. juill, vol.16, issue.2, pp.141-147, 1983.

S. Babalonis, M. Haney, R. J. Malcolm, M. R. Lofwall, V. R. Votaw et al., Oral cannabidiol does not produce a signal for abuse liability in frequent marijuana smokers. Drug and Alcohol Dependence, vol.172, pp.9-13, 2017.

V. Katsidoni, I. Anagnostou, and G. Panagis, Cannabidiol inhibits the reward-facilitating effect of morphine: involvement of 5-HT 1A receptors in the dorsal raphe nucleus: Cannabidiol and brain reward, Addiction Biology. mars, vol.18, issue.2, pp.286-96, 2013.

J. Corroon and J. A. Phillips, A Cross-Sectional Study of Cannabidiol Users, Cannabis Cannabinoid Res, vol.3, issue.1, pp.152-61, 2018.

S. Turner, N. Mota, J. Bolton, and J. Sareen, Self-medication with alcohol or drugs for mood and anxiety disorders: A narrative review of the epidemiological literature, Depress Anxiety, vol.35, issue.9, pp.851-60, 2018.

J. M. Bolton, J. Robinson, and J. Sareen, Self-medication of mood disorders with alcohol and drugs in the National Epidemiologic Survey on Alcohol and Related Conditions, J Affect Disord. juin, vol.115, issue.3, pp.367-75, 2009.

J. Robinson, J. Sareen, B. J. Cox, and J. Bolton, Self-medication of anxiety disorders with alcohol and drugs: Results from a nationally representative sample, J Anxiety Disord. janv, vol.23, issue.1, pp.38-45, 2009.

A. Mané, M. Fernández-expósito, D. Bergé, L. Gómez-pérez, A. Sabaté et al., Relationship between cannabis and psychosis: Reasons for use and associated clinical variables, Psychiatry Res, vol.229, issue.1-2, pp.70-74, 2015.

S. Spilka, L. Nézet, O. , L. Tovar, and M. , Estimations 2011 des consommations de produits psychoactifs à 17 ans. Observatoire français des drogues et des toxicomanies, 2011.

, XLSTAT version 2019

. Xlstat, Your data analysis solution

D. Sur,

D. D. Satre, A. Leibowitz, S. A. Sterling, Y. Lu, A. Travis et al., A randomized clinical trial of Motivational Interviewing to reduce alcohol and drug use among patients with depression, J Consult Clin Psychol. juill, vol.84, issue.7, pp.571-580, 2016.

P. J. Gates, P. Sabioni, J. Copeland, L. Foll, B. Gowing et al., Psychosocial interventions for cannabis use disorder, Cochrane Database Syst Rev. 5 mai, issue.5, p.5336, 2016.

J. Bell, C. S. Die-kacou, H. Grégoire, J. Hutangkabodee, S. Lakhal et al., The Role of the pharmacist in self-care and self-medication, 1998.

, Automédication : les bonnes pratiques

, Conseil National de l'Ordre des Médecins, 2019.

R. Z. Horth, B. Crouch, B. Z. Horowitz, A. Prebish, M. Slawson et al., Notes from the Field: Acute Poisonings from a Synthetic Cannabinoid Sold as Cannabidiol -Utah, MMWR Morbidity and Mortality Weekly Report. 25 mai, vol.67, issue.20, pp.587-595, 2017.

A. Hazekamp, The Trouble with CBD Oil, Med Cannabis Cannabinoids. 12 juin, vol.1, issue.1, pp.65-72, 2018.

, Annexe 2 -Réponse par email de la CNIL Bonjour Monsieur Marc MOINAS, Nous vous remercions de nous avoir contactés

, Dans le cadre de la réalisation de votre thèse en tant qu'interne en DES de psychiatrie, vous souhaitez savoir si vous avez des formalités à effectuer auprès de notre Commission

, Je vous indique que si les données que vous collectez sont anonymes, c'est-à-dire qu'elles ne vous permettent pas d'identifier directement ou indirectement une personne physique, dans ce cas il ne s'agit pas de données à caractère personnel

, Recherche médicale : comment procéder pour une thèse ou un mémoire